Benzinga | Sep 17, 2021 07:09AM EDT

BMO Capital Maintains Outperform on NGM Biopharmaceuticals, Raises Price Target to $35

BMO Capital analyst Matthew Luchini maintains NGM Biopharmaceuticals (NASDAQ:NGM) with a Outperform and raises the price target from $29 to $35.